JP2007535930A - 皮膚の炎症を予測するためのｉｌ−１７発現の使用；処置方法 - Google Patents

皮膚の炎症を予測するためのｉｌ−１７発現の使用；処置方法 Download PDF

Info

Publication number
JP2007535930A
JP2007535930A JP2007511437A JP2007511437A JP2007535930A JP 2007535930 A JP2007535930 A JP 2007535930A JP 2007511437 A JP2007511437 A JP 2007511437A JP 2007511437 A JP2007511437 A JP 2007511437A JP 2007535930 A JP2007535930 A JP 2007535930A
Authority
JP
Japan
Prior art keywords
skin
expression
subject
antibody
psoriasis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007511437A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007535930A5 (enExample
Inventor
ロバート エー． カステレイン，
テリル ケー． マックラナハン，
エリン マーフィー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2007535930A publication Critical patent/JP2007535930A/ja
Publication of JP2007535930A5 publication Critical patent/JP2007535930A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2007511437A 2004-05-03 2005-05-02 皮膚の炎症を予測するためのｉｌ−１７発現の使用；処置方法 Pending JP2007535930A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56774704P 2004-05-03 2004-05-03
PCT/US2005/014720 WO2005108616A1 (en) 2004-05-03 2005-05-02 Use of il-17 expression to predict skin inflammation; methods of treatment

Publications (2)

Publication Number Publication Date
JP2007535930A true JP2007535930A (ja) 2007-12-13
JP2007535930A5 JP2007535930A5 (enExample) 2008-06-19

Family

ID=34967584

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007511437A Pending JP2007535930A (ja) 2004-05-03 2005-05-02 皮膚の炎症を予測するためのｉｌ−１７発現の使用；処置方法

Country Status (11)

Country Link
US (2) US7501247B2 (enExample)
EP (1) EP1761643A1 (enExample)
JP (1) JP2007535930A (enExample)
CN (1) CN1993480A (enExample)
AU (1) AU2005241020B2 (enExample)
BR (1) BRPI0510617A (enExample)
CA (1) CA2565566A1 (enExample)
MX (1) MXPA06012754A (enExample)
NO (1) NO20065560L (enExample)
WO (1) WO2005108616A1 (enExample)
ZA (1) ZA200609140B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012524067A (ja) * 2009-04-15 2012-10-11 ノースウェスタン ユニバーシティ オリゴヌクレオチド機能化ナノ粒子の送達
JP2021523735A (ja) * 2018-05-09 2021-09-09 ダームテック，インク． 自己免疫疾患における新規な遺伝子分類とその使用

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7422743B2 (en) * 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
US20070160576A1 (en) * 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
DK1576011T3 (da) 2002-10-30 2009-11-30 Genentech Inc Inhibering af IL-17 produktion
US7247711B2 (en) * 2003-05-09 2007-07-24 Centocor, Inc. IL-23p40 specific antibody
BRPI0510617A (pt) * 2004-05-03 2007-10-30 Schering Corp uso de expressão de il-17 para prever inflamação de pele; processos de tratamento
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
EP1671642A1 (en) * 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
US7704503B2 (en) * 2005-02-14 2010-04-27 Wyeth Llc Use of IL-17F in diagnosis and therapy of airway inflammation
PT1896073E (pt) 2005-06-30 2013-05-28 Janssen Biotech Inc Composições, métodos e aplicações de anticorpos anti-il-23
CN101296706B (zh) * 2005-09-01 2011-11-30 先灵公司 Il-23和il-17拮抗剂治疗自身免疫性眼部炎性疾病的用途
AU2006330411B2 (en) 2005-12-29 2012-07-12 Janssen Biotech, Inc. Human anti-IL-23 antibodies, compositions, methods and uses
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
AU2007261019A1 (en) * 2006-06-19 2007-12-27 Wyeth Methods of modulating IL-22 and IL-17
US7846443B2 (en) 2006-08-11 2010-12-07 Schering Corporation Antibodies to IL-17A
EP2417974A1 (en) * 2007-02-28 2012-02-15 Schering Corporation Combination therapy for treatment of immune disorders
WO2008134659A2 (en) * 2007-04-27 2008-11-06 Zymogenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
KR20170023209A (ko) 2008-05-05 2017-03-02 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
EP2294216A4 (en) 2008-05-14 2011-11-23 Dermtech Int DIAGNOSIS OF MELANOMA AND SOLAR LENTIGO BY ANALYSIS OF NUCLEIC ACIDS
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
PE20120815A1 (es) 2009-05-05 2012-07-08 Novimmune Sa Anticuerpos anti il-17f y metodos de uso de los mismos
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
AU2010313304B2 (en) 2009-10-30 2015-08-20 Janssen Biotech, Inc. IL-17A antagonists
WO2012061448A1 (en) 2010-11-04 2012-05-10 Boehringer Ingelheim International Gmbh Anti-il-23 antibodies
JP6279467B2 (ja) * 2011-06-27 2018-02-14 ガルデルマ・リサーチ・アンド・デヴェロップメント ざ瘡についての新規ｔｈ１７分化マーカーおよびその使用
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
US11078265B2 (en) 2012-05-03 2021-08-03 Boehringer Ingelheim International Gmbh Anti-IL-23 antibodies
CN104884473B (zh) 2012-05-22 2019-12-03 百时美施贵宝公司 Il-17a/f il-23双特异性抗体及其应用
WO2016014775A1 (en) 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
WO2016036918A1 (en) 2014-09-03 2016-03-10 Boehringer Ingelheim International Gmbh Compound targeting il-23a and tnf-alpha and uses thereof
BR112017014684A2 (en) 2015-02-04 2018-01-09 Boehringer Ingelheim International Gmbh methods of treatment of inflammatory diseases
JP2018521047A (ja) * 2015-07-16 2018-08-02 イーライ リリー アンド カンパニー 掻痒の治療
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
KR102617833B1 (ko) 2016-05-06 2023-12-27 엑시큐어 오퍼레이팅 컴퍼니 인터류킨 17 수용체 mRNA의 특이적 녹다운을 위한 안티센스 올리고뉴클레오티드 (ASO)를 제시하는 리포좀성 구형 핵산 (SNA) 구축물
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
US11976332B2 (en) 2018-02-14 2024-05-07 Dermtech, Inc. Gene classifiers and uses thereof in non-melanoma skin cancers
CA3092551A1 (en) 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
BR112021009287A2 (pt) 2018-11-20 2021-10-26 Janssen Biotech, Inc. Método seguro e eficaz para tratar psoríase com anticorpo específico anti-il-23
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
EP4596046A3 (en) 2020-05-21 2025-10-22 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000055204A1 (en) * 1999-03-16 2000-09-21 Human Genome Sciences, Inc. Interleukin 17 receptor-like protein
JP2002515246A (ja) * 1998-05-15 2002-05-28 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療用途
WO2002078729A1 (en) * 2001-03-29 2002-10-10 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
WO2002102411A2 (en) * 2001-01-25 2002-12-27 Zymogenetics, Inc. Method for treating psoriasis by using an il-17d antagonist
JP2003527104A (ja) * 1999-12-23 2003-09-16 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療上の用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046420A2 (en) * 1999-12-23 2001-06-28 Genentech, Inc. Il-17 and il-17r homologous polypeptides and therapeutic uses thereof
US20030083231A1 (en) 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
EP1287130B2 (en) * 2000-05-10 2017-07-26 Merck Sharp & Dohme Corp. Mammalian cytokine receptor subunit proteins, related reagents and methods
DK1576011T3 (da) * 2002-10-30 2009-11-30 Genentech Inc Inhibering af IL-17 produktion
WO2004058178A2 (en) * 2002-12-23 2004-07-15 Schering Corporation Uses of mammalian cytokine; related reagents
DE60336930D1 (de) 2002-12-31 2011-06-09 Schering Corp IL-27 et IL-2 pour le traitement du cancer
US7247711B2 (en) * 2003-05-09 2007-07-24 Centocor, Inc. IL-23p40 specific antibody
EP1641822B1 (en) 2003-07-08 2013-05-15 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
US7501427B2 (en) * 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US7183057B2 (en) 2004-03-31 2007-02-27 Dermtech International Tape stripping methods for analysis of skin disease and pathological skin state
US20050287593A1 (en) * 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
BRPI0510617A (pt) * 2004-05-03 2007-10-30 Schering Corp uso de expressão de il-17 para prever inflamação de pele; processos de tratamento

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515246A (ja) * 1998-05-15 2002-05-28 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療用途
WO2000055204A1 (en) * 1999-03-16 2000-09-21 Human Genome Sciences, Inc. Interleukin 17 receptor-like protein
JP2003527104A (ja) * 1999-12-23 2003-09-16 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療上の用途
WO2002102411A2 (en) * 2001-01-25 2002-12-27 Zymogenetics, Inc. Method for treating psoriasis by using an il-17d antagonist
WO2002078729A1 (en) * 2001-03-29 2002-10-10 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012524067A (ja) * 2009-04-15 2012-10-11 ノースウェスタン ユニバーシティ オリゴヌクレオチド機能化ナノ粒子の送達
JP2021523735A (ja) * 2018-05-09 2021-09-09 ダームテック，インク． 自己免疫疾患における新規な遺伝子分類とその使用
JP7431812B2 (ja) 2018-05-09 2024-02-15 ダームテック，インク． 自己免疫疾患における新規な遺伝子分類とその使用

Also Published As

Publication number Publication date
CN1993480A (zh) 2007-07-04
BRPI0510617A (pt) 2007-10-30
US20050244874A1 (en) 2005-11-03
EP1761643A1 (en) 2007-03-14
US7776540B2 (en) 2010-08-17
ZA200609140B (en) 2007-11-28
US20090028860A1 (en) 2009-01-29
AU2005241020A1 (en) 2005-11-17
MXPA06012754A (es) 2007-02-19
US7501247B2 (en) 2009-03-10
CA2565566A1 (en) 2005-11-17
NO20065560L (no) 2006-12-01
AU2005241020B2 (en) 2008-07-10
WO2005108616A1 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
US7501247B2 (en) Method of treating skin inflammation
US8178095B2 (en) Method of treating skin inflammation
Li et al. Delayed microglial depletion after spinal cord injury reduces chronic inflammation and neurodegeneration in the brain and improves neurological recovery in male mice
Visvanathan et al. Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab
Choy et al. Comparative transcriptomic analyses of atopic dermatitis and psoriasis reveal shared neutrophilic inflammation
Gittler et al. Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis
KR102197524B1 (ko) 특발성 폐 섬유증의 예후, 진단 및 치료 방법
Kawasaki et al. Up-regulated gene expression in the conjunctival epithelium of patients with Sjögren's syndrome
US20020111290A1 (en) Uses of mammalian genes and related reagents
McColl et al. TLR7-mediated skin inflammation remotely triggers chemokine expression and leukocyte accumulation in the brain
Ugurel et al. Enhanced NLRP3 and DEFA1B expression during the active stage of parenchymal neuro-behçet's disease
Sasaki-Iwaoka et al. AS2762900-00, a potent anti-human IL-23 receptor monoclonal antibody, prevents epidermal hyperplasia in a psoriatic human skin xenograft model
US20250282859A1 (en) Use of il-36 inhibitors for the treatment of netherton syndrome
JP2007513163A (ja) サイトカイン活性を調節する方法；関連試薬
Hong Act1-Mediated RNA Metabolism in IL-17-Driven Inflammatory Diseases
WO2018207182A1 (en) Biomarker for anti-tnf therapy in retinal diseases
EP4619434A2 (en) Biomarker-based treatment and diagnostic methods for il-17-dependent conditions
Chaudhry Investigation of systemic inflammation in aneurysmal subarachnoid hemorrhage (aSAH) and its impact on post-aSAH complications
JP2006174740A (ja) アレルギー性疾患の疾患マーカーおよびその利用
HK1242740A1 (en) Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
Belperio et al. IL-13 Is Pivotal in the Fibro-Obliterative
Chujo et al. Connective Tiue Growth Factor Causes Persistent Proα2 (I) Collagen Gene Expreion Induced by Transforming Growth Factor-β in a Mouse Fibrosis Model

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110412

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110509

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110905